Movement Alert｜REMEGEN falls 5.01% in Regular Trading, second A-share buyback this year fails to ease pressure

Market Focus11-03 13:18

On November 3, REMEGEN fell 5.01% in Regular Trading, trading at HK$62.5, with turnover of HK$85.97 million.

The clearest catalyst in public disclosures is an event-driven update: the company announced a second A-share buyback plan this year, proposing to repurchase shares worth RMB30 million to RMB60 million at up to RMB131 per share to safeguard company value and shareholder interests.

REMEGEN also disclosed progress on its first buyback plan. By October 31, it had cumulatively repurchased about 60,040 A shares, or roughly 0.01% of total share capital, for about RMB6.63 million excluding transaction costs, with executed prices between RMB108.3 and RMB113.7 per share. Despite these shareholder-support measures, biotechnology names were broadly weak on the day, with sector pressure likely limiting the market impact of the buyback signal.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment